Sperling, Adam S.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 875

The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K

Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 433

Small-molecule-induced polymerization triggers degradation of BCL6

Słabicki, M., Yoon, H., Koeppel, J., Nitsch, L., Roy Burman, S. S., Di Genua, C., Donovan, K. A., Sperling, A. S., Hunkeler, M., Tsai, J. M., et al. (2020) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 270

Association of clonal hematopoiesis with chronic obstructive pulmonary disease

Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., et al. (2022) · Blood

Chronic Obstructive Pulmonary Disease (COPD) ResearchAcute Myeloid Leukemia Research

Cited by 235

Histone H3 Lysine 56 Acetylation Is Linked to the Core Transcriptional Network in Human Embryonic Stem Cells

Xie, W., Song, C., Young, N. L., Sperling, A. S., Xu, F., Sridharan, R., Conway, A. E., Garcia, B. A., Plath, K., Clark, A. T., et al. (2009) · Molecular Cell

Genomics and Chromatin DynamicsEpigenetics and DNA Methylation

Cited by 197

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 137

UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability

Tsai, J. M., Aguirre, J. D., Li, Y.-D., Brown, J., Focht, V., Kater, L., Kempf, G., Sandoval, B., Schmitt, S., Rutter, J. C., et al. (2023) · Molecular Cell

Estrogen and related hormone effectsUbiquitin and proteasome pathways

Cited by 68

Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216

Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y.-D., Sperling, A. S., Zhang, T., Ebert, B. L., et al. (2022) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 63

Immuno-PRISM: A Randomized Phase II Platform Study of Bispecific Antibodies in High-Risk Smoldering Myeloma

Nadeem, O., Magidson, S., Midha, S., O'Donnell, E. K., Hartley-Brown, M. A., Sperling, A. S., Redd, R. A., Marto, M., Davie, C., Ricciardi, C., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 37

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 16